99 related articles for article (PubMed ID: 23441448)
21. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
22. Frequent hypermethylation of the RASSF1A gene in prostate cancer.
Liu L; Yoon JH; Dammann R; Pfeifer GP
Oncogene; 2002 Oct; 21(44):6835-40. PubMed ID: 12360410
[TBL] [Abstract][Full Text] [Related]
23. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids.
Goessl C; Krause H; Müller M; Heicappell R; Schrader M; Sachsinger J; Miller K
Cancer Res; 2000 Nov; 60(21):5941-5. PubMed ID: 11085508
[TBL] [Abstract][Full Text] [Related]
24. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
Vanaja DK; Ballman KV; Morlan BW; Cheville JC; Neumann RM; Lieber MM; Tindall DJ; Young CY
Clin Cancer Res; 2006 Feb; 12(4):1128-36. PubMed ID: 16489065
[TBL] [Abstract][Full Text] [Related]
25. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer.
Akino K; Toyota M; Suzuki H; Mita H; Sasaki Y; Ohe-Toyota M; Issa JP; Hinoda Y; Imai K; Tokino T
Gastroenterology; 2005 Jul; 129(1):156-69. PubMed ID: 16012945
[TBL] [Abstract][Full Text] [Related]
26. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
28. [Role of RASSF1A hypermethylation in prostate cancer].
Wang YC; Yu ZH; Chen LB
Zhonghua Nan Ke Xue; 2007 Sep; 13(9):822-5. PubMed ID: 17929562
[TBL] [Abstract][Full Text] [Related]
29. A quantitative promoter methylation profile of prostate cancer.
Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
[TBL] [Abstract][Full Text] [Related]
30. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
Zhang Y; Miao Y; Yi J; Wang R; Chen L
Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic inactivation of PCDH10 in human prostate cancer cell lines.
Li Z; Li W; Xie J; Wang Y; Tang A; Li X; Ye J; Gui Y; Cai Z
Cell Biol Int; 2011 Jul; 35(7):671-6. PubMed ID: 21314642
[TBL] [Abstract][Full Text] [Related]
32. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences.
Schagdarsurengin U; Richter AM; Hornung J; Lange C; Steinmann K; Dammann RH
Mol Cancer; 2010 Sep; 9():264. PubMed ID: 20920251
[TBL] [Abstract][Full Text] [Related]
33. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types.
Krop I; Player A; Tablante A; Taylor-Parker M; Lahti-Domenici J; Fukuoka J; Batra SK; Papadopoulos N; Richards WG; Sugarbaker DJ; Wright RL; Shim J; Stamey TA; Sellers WR; Loda M; Meyerson M; Hruban R; Jen J; Polyak K
Mol Cancer Res; 2004 Sep; 2(9):489-94. PubMed ID: 15383627
[TBL] [Abstract][Full Text] [Related]
34. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.
Meiers I; Shanks JH; Bostwick DG
Pathology; 2007 Jun; 39(3):299-304. PubMed ID: 17558856
[TBL] [Abstract][Full Text] [Related]
35. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
Collard RL; Harya NS; Monzon FA; Maier CE; O'Keefe DS
Prostate; 2006 May; 66(7):687-95. PubMed ID: 16425203
[TBL] [Abstract][Full Text] [Related]
36. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
Zhao H; Shiina H; Greene KL; Li LC; Tanaka Y; Kishi H; Igawa M; Kane CJ; Carroll P; Dahiya R
Cancer; 2005 Jul; 104(1):44-52. PubMed ID: 15895377
[TBL] [Abstract][Full Text] [Related]
37. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
Rehman I; Cross SS; Catto JW; Leiblich A; Mukherjee A; Azzouzi AR; Leung HY; Hamdy FC
Prostate; 2005 Dec; 65(4):322-30. PubMed ID: 16015609
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
40. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
